Across TCGA pan-cancer cohorts, FKBP3 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated FKBP3 data layer compared with 29 for mass-spec protein and 5 for mass-spec protein.
The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher FKBP3 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated FKBP3 expression acts as an unfavorable survival marker.
BLCA, LUSC, and UCEC are the cancer types where FKBP3 Mutation most reproducibly stratifies survival.